Cervical Cancer

Researchers Confirm Link Between HPV And Head And Neck Cancer But Europe-wide Survey Shows Woeful Public Ignorance On Role Of Oral Sex
Human papillomavirus (HPV) is an important causative agent in squamous cell cancers of head and neck (HNSCC) a new meta-analysis presented at the American Society of Clinical Oncology (ASCO) confirms; but a separate European survey at the same meeting reveals the public is woefully ignorant about it and possible ways to avoid it.

Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmö, Sweden.

Study: Benefit To Women Not Enough To Sway Men To Get HPV Vaccine
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.

FDA Recommends Gardasil Recipients Sit, Lie Down After Receiving Vaccination
In a posting aimed at health care professionals, FDA on its Web site on Wednesday said that recipients of Merck's human papillomavirus vaccine, Gardasil, should be closely observed afterward for 15 minutes while they remain seated or lying down to avoid the possibility of fainting, the Wall Street Journal reports.

Merck's Gardasil Effective At Preventing HPV, Cervical Disease In Older Women, Study Finds
Merck's human papillomavirus vaccine, Gardasil, was 90% effective in preventing infection with the virus and cervical disease in women ages 24 to 45, according to a study published Monday in the medical journal Lancet,

No Improvement In Detecting Cervical Cancer With Addition Of HPV Test In Cervical Screening Programme In The UK
An article published Online First and in the July edition of The Lancet Oncology reports that the combination of human papillomavirus (HPV) testing with regular liquid-based cytology (LBC) screening does not improve the detection of cervical cancer compared with LBC screening alone. In the UK, liquid-based cytology (which is a liquid form of the Pap smear test) has replaced the conventional Pap smear test.

BSD Receives FDA Humanitarian Use Designation For The BSD-2000 Hyperthermia System
BSD Medical Corporation (NASDAQ:BSDM) announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Use Device (HUD) designation for the company's BSD-2000 Hyperthermia System for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy.

The Improvement Foundation - Helping Tackle The Decline In Cervical Cancer Screening Uptake
Cervical Cancer Awareness Week 8-14 June 2009 is a key time to remind women that it is of huge importance that they attend their screening appointment when asked. The Improvement Foundation (IF) aim to help tackle the decline in screening uptake by addressing levels of complacency among clinicians and the public through their national Cervical Screening Improvement Programme.

Study: Benefit To Women Not Enough To Sway Men To Get HPV Vaccine
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.

FDA Recommends Gardasil Recipients Sit, Lie Down After Receiving Vaccination
In a posting aimed at health care professionals, FDA on its Web site on Wednesday said that recipients of Merck's human papillomavirus vaccine, Gardasil, should be closely observed afterward for 15 minutes while they remain seated or lying down to avoid the possibility of fainting, the Wall Street Journal reports.

Merck's Gardasil Effective At Preventing HPV, Cervical Disease In Older Women, Study Finds
Merck's human papillomavirus vaccine, Gardasil, was 90% effective in preventing infection with the virus and cervical disease in women ages 24 to 45, according to a study published Monday in the medical journal Lancet,

Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmö, Sweden.

Lack Of Information Fuels Cancer Screening Fears According To Review Covering Nearly 6,000 Women
Fear plays a major role in whether women decide to go for cancer screening or not, but healthcare providers underestimate how much women need to know and wrongly assume that they will ask for information if they want it. Those are the two key findings from a study published in the June issue of the UK-based Journal of Advanced Nursing.

Women Previously Diagnosed With Abnormal Cervical Cell Growth At Higher Risk For Recurrence And Invasive Cancer
New research from the UC Davis Center for Healthcare Policy and Research has found that women who have been treated for cervical intraepithelial neoplasia (abnormal cervical cell growth), are at higher risk for a recurrence of the disease or invasive cervical cancer.

New Surgical Technique Shows Promising Results For Patients With Cervical Cancer
A new surgical technique could allow surgeons to perform a radical hysterectomy in patients with early-stage cervical cancer-with fewer complications, reduced morbidity, and a lower risk of local tumour recurrence than current surgical methods, according to an Article published Online first and in the July edition of The Lancet Oncology.

New Surgical Technique Shows Promising Results For Patients With Cervical Cancer
A new surgical technique could allow surgeons to perform a radical hysterectomy in patients with early-stage cervical cancer-with fewer complications, reduced morbidity, and a lower risk of local tumour recurrence than current surgical methods, according to an Article published Online first and in the July edition of The Lancet Oncology.

CDC Weighs Changes To Mandate That Young Immigrant Women Receive HPV Vaccine
Immigration and women's health advocates hope that the Centers for Disease Control and Prevention's ongoing review of vaccination requirements for immigrants results in the elimination of a mandate that female immigrants receive Merck's human papillomavirus vaccine Gardasil, the

Human Papilloma Virus Vaccine Effective In Women Aged 24-45 Not Previously Exposed
An article published Online First and in an upcoming edition of The Lancet reports that women aged between 24 and 45 can be protected by the human papilloma virus (HPV) vaccine, if they have not been already infected by the virus. The report is the work of Dr Nubia Muñoz, from the National Institute of Cancer, Bogotá, Colombia, and collaborators. Over the last thirty years, sexual behavior has changed. The age of the first marriage is rising, divorce rates are augmenting.

Advaxis Receives FDA Response To Orphan Drug Filing
Advaxis, Inc. (OTCBB:ADXS) received the FDA letter late on June 1 denying the company's request for Orphan Drug Designation (ODD) for the use of ADXS11-001 in invasive cervix cancer. The FDA stated their market definition for invasive cervical cancer prevalence (including all those who had been cured) is over the 200,000 person cutoff.

GSK Awaits FDA Decision On Cervarix HPV Vaccine, Hopes To Compete With Merck's Gardasil
FDA is expected to make a decision in the next several months over whether to approve GlaxoSmithKline's human papillomavirus vaccine Cervarix for the U.S. market, the AP/Philadelphia Inquirer reports.

New Study Results Further Support The Evidence That The HPV Vaccine Gardasil(R)will Provide Long-lasting Protection
New results from an extended follow-up study further support the evidence that protection provided by the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® should be long-lasting. The study, which was part of the clinical development programme for the quadrivalent vaccine, looked at the one-type (16) HPV "Proof of Principle" (phase II) vaccine and found that on average 8 years and up to 9.

GARDASIL(R) Is First Cervical Cancer Vaccine To Receive WHO Pre-qualification
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.

New Study Results Further Support The Evidence That The HPV Vaccine Gardasil(R)will Provide Long-lasting Protection
New results from an extended follow-up study further support the evidence that protection provided by the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® should be long-lasting. The study, which was part of the clinical development programme for the quadrivalent vaccine, looked at the one-type (16) HPV "Proof of Principle" (phase II) vaccine and found that on average 8 years and up to 9.

Four-type HPV Vaccine Receives WHO Pre-qualification
The four-type (6, 11, 16, 18) human papillomavirus (HPV) vaccine, Gardasil® has been awarded World Health Organization (WHO) pre-qualification. It is the first cervical cancer vaccine to receive WHO pre-qualification.

CDC To Review Vaccine Policies; Immigrant, Women's Rights Advocates Anticipating Repeal Of HPV Vaccine Requirement
A coalition of more than 100 groups representing women, immigrants, and public health and reproductive rights advocates are hoping CDC will repeal its rule requiring female immigrants seeking U.S. citizenship to receive the human papillomavirus vaccine Gardasil, the

New Broad-Spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals
Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute.

New Broad-Spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals
Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute.

Studies Of GARDASIL(R), Merck's Cervical Cancer Vaccine, And HPV 16 Vaccine Component Of GARDASIL Presented At International Papillomavirus Conference
In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration. The women enrolled in this study are a subset of the original Phase II HPV 16 proof-of-concept study published in 2002. Follow up ranged from 7.2 years to up to 9.5 years.

Cervical Cancer Vaccine Reaches Vanuatu
A Brisbane team are working closely with the Vanuatu Government to trial a program for effective delivery of cervical cancer vaccines to schoolgirls in resource-poor settings. Headed by cervical cancer vaccine pioneer Professor Ian Frazer from UQ's